Title:

Treatment and CSYNC™ satisfaction with glatiramer acetate 20mg/ml once daily vs. glatiramer acetate 40mg/ml three times a week in RRMS patients: a patient survey

Survey on satisfaction with glatiramer acetate

Authors:

Deborah Maes (main author) ; Medical Department, Teva Pharma Belgium, Laarstraat 16, 2610 Wilrijk

Virginie Mauro; MS Care Patient Support Program, Quintiles Belgium, Medialaan 32, 1800 Vilvoorde

Geert Van Gassen; Medical Department, Teva Pharma Belgium, Laarstraat 16, 2610 Wilrijk

Danny Decoo; Neurology department, AZ Alma, Ringlaan 15, 9900 Eeklo

Abstract:

Glatiramer acetate (GA), Copaxone®, is approved for reducing relapse frequency in patients with RRMS, originally as a 20mg/ml daily subcutaneous (sc) injection. The GALA-study (NCT01067521) demonstrated that, compared with placebo, treatment with GA 40mg/ml sc three times a week (tiw) reduced total number of confirmed relapses significantly in patients with RRMS over a 12-month period. The GLACIER (NCT01874145) study showed a 50% reduction in the rate of injection related adverse events and injection site reactions. Teva Pharmaceuticals developed the CSYNC™, an autoinjector, for improved ergonomics, ease-of-use and accuracy.

The aim of the patient survey was to compare treatment and CSYNC™ satisfaction in RRMS patients being treated with GA 20mg/ml daily vs. GA 40mg/ml tiw, using the CSYNC™ autoinjector.

Participants were RRMS patients taking part in the Belgian Copaxone Patient Support Program, initially using GA 20mg/ml once daily and who were switched to GA 40mg/ml tiw. The 196 participants filled out the treatment satisfaction questionnaire for medication score (TSQM-9) and a questionnaire assessing satisfaction with the CSYNC™ autoinjector.

The 9 questions of the TSQM-9 can be classified in three subscales: effectiveness, convenience and global satisfaction. Mean scores on the effectiveness and the global satisfaction questions of the TSQM-9 and mean scores on the questions assessing patient satisfaction with CSYNC™ autoinjector were not significantly different between the two treatment regimens. However, a significant difference of GA 40mg/ml tiw on all three convenience questions of the TSQM-9 when compared to GA 20mg/ml daily was shown: GA 40mg/ml tiw is perceived as easier to use (p=0,001), easier to plan (p=0,0006) and more convenient to take as instructed (p<0,00001). The results of the patient survey show an overall satisfaction on GA treatment for both formulations with the the CSYNC™ autoinjector and a higher convenience for GA 40mg/ml compared to GA 20mg/ml.